Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,237 INR | +2.66% | +5.39% | +11.16% |
Mar. 27 | Ipca Laboratories Licenses Anti-Cancer Biosimilar Technology to Omexa Formulary | MT |
Feb. 19 | Nomura Adjusts IPCA Laboratories Price Target to INR1,308 From INR1,113, Keeps at Buy | MT |
- Stock
- Equities
- Stock Ipca Laboratories Limited - NSE India S.E.
- News Ipca Laboratories Limited